Related Experiment Video
Updated: May 16, 2026
A Macrophage-Tumor Spheroid Co-Invasion Assay
Published on: January 24, 2025
Flipping the script on macrophages in leiomyosarcoma
Badreddin Edris1, Kipp Weiskopf, Irving L Weissman
1Department of Pathology; Stanford University School of Medicine; Stanford, CA USA ; Department of Genetics; Stanford University School of Medicine; Stanford, CA USA.
Abstract:
Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growth and metastases. Therefore, anti-CD47 mAbs represent a promising targeted immunotherapy for LMS.
Insights
Targeting CD47 on leiomyosarcoma (LMS) tumor cells with antibodies enables macrophages to engulf and eliminate cancer cells. This approach shows promise for treating LMS by preventing tumor growth and metastasis.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Macrophages play a crucial role in promoting the growth of leiomyosarcoma (LMS), a rare and aggressive soft-tissue cancer.
- The CD47 protein on the surface of LMS cells interacts with the signal regulatory protein α (SIRPα) on macrophages, inhibiting phagocytosis (cellular engulfment).
Purpose of the Study:
- To investigate the therapeutic potential of targeting the CD47-SIRPα axis in leiomyosarcoma.
- To evaluate the efficacy of anti-CD47 monoclonal antibodies (mAbs) in overcoming macrophage-mediated immune evasion in LMS.
Main Methods:
- Utilized anti-CD47 monoclonal antibodies (mAbs) in a preclinical model of leiomyosarcoma.
- Assessed the ability of macrophages to phagocytose LMS cells following treatment with anti-CD47 mAbs.
- Evaluated the impact of anti-CD47 mAb treatment on tumor growth and metastasis.
Main Results:
- Anti-CD47 mAbs successfully enabled macrophages to engulf and eliminate leiomyosarcoma cells.
- Treatment with anti-CD47 mAbs significantly inhibited tumor growth.
- Metastatic spread of leiomyosarcoma was reduced following anti-CD47 mAb therapy.
Conclusions:
- The CD47-SIRPα signaling pathway is a critical mechanism of immune evasion in leiomyosarcoma.
- Anti-CD47 monoclonal antibodies represent a viable targeted immunotherapy strategy for LMS.
- This approach holds promise for preventing leiomyosarcoma progression and metastasis.
